Three clinical trial platforms working together to test the effects of full doses of anticoagulants (blood thinners) in COVID-19 patients have paused enrollment for one group of patients.

Among critically ill COVID-19 patients requiring intensive care unit (ICU) support, therapeutic anticoagulation drugs did not reduce the need for organ support.

Enrollment continues for moderately ill hospitalized COVID-19 patients in the trials.

As is normal for clinical trials, these trials are overseen by independent boards that routinely review the data and are composed of experts in ethics, biostatistics, clinical trials, and blood clotting disorders.

Informed by the deliberations of these oversight boards, all the trial sites have paused enrollment of the most critically ill hospitalized patients with COVID-19.

Read More